Is a Normal TSH Synonymous With “Euthyroidism” in Levothyroxine Monotherapy?
Open accessThe DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
Context: Levothyroxine (LT4) monotherapy is the standard of care for hypothyroidism. Objective: To determine whether LT4 at doses that normalize the serum TSH is associated with normal markers of thyroid status. Design: Cross-sectional data from the US National Health and Nutrition Examination Survey (2001–2012) was used to evaluate 52 clinical parameters. LT4 users were compared to healthy controls and controls matched for age, sex, race, and serum TSH. Regression was used to evaluate for correlation with T4 and T3 levels. Participants: A total of 9981 participants with normal serum TSH were identified; 469 were LT4-treated. Results: Participants using LT4 had higher serum total and free T4 and lower serum total and free T3 than healthy or matched controls. This translated to approximately 15–20% lower serum T3:T4 ratios in LT4 treatment, as has been shown in other cohorts. In comparison to matched controls, LT4-treated participants had higher body mass index despite report of consuming fewer calories/day/kg; were more likely to be taking beta-blockers, statins, and antidepressants; and reported lower total metabolic equivalents. A serum TSH level below the mean in LT4-treated participants was associated with a higher serum free T4 but similar free and total T3; yet those with lower serum TSH levels exhibited higher serum high-density lipoprotein and lower serum low-density lipoprotein, triglycerides, and C-reactive protein. Age was negatively associated with serum free T3:free T4 ratio in all participants; caloric intake was positively associated in LT4-treated individuals. Conclusions: In a large population study, participants using LT4 exhibited lower serum T3:T4 ratios and differed in 12/52 objective and subjective measures.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In fact, in a cross-sectional study based on the U.S. National Health and Nutrition Examination Survey data base, serum T3 and fT3 levels were 10% lower in LT4-treated patients than in a control group matched for sex, age, ethnic background, and TSH levels (13).”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many patients with hypothyroidism also have other chronic medical conditions (13).”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“NHANES data show that patients on levothyroxine are 54% more likely to be on statins than controls matched for age, sex, and ethnic background.178”
From Hypothyroidism (2024) · cites this paper as [178]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LT4-treated patients weigh ∼10 pounds more (14)”
From Liothyronine and Desiccated Thyroid Extract in the Treatment of Hypothyroidism (2020) · cites this paper as [14]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A normal serum TSH level consequently does not necessarily indicate a euthyroid state at the tissue level [49].”
From T4+T3 Combination Therapy: An Unsolved Problem of Increasing Magnitude and Complexity (2021) · cites this paper as [49]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., et al. (2014) · Thyroid® · doi:10.1089/thy.2014.0028 · Cited by 1,928 · cited 3×
“The dogma in clinical thyroidology that LT4 monotherapy at doses that normalize serum TSH is sufficient to restore euthyroidism (1, 2) has come into question as evidence suggests a significant proportion of patients treated with LT4 continue to experience residual symptoms of hypothyroidism, including psychological (6…”
BackgroundSelf-citation(1952) · Diabetes · doi:10.2337/diab.1.2.159 · Cited by 1,447
The epidemiology of thyroid disease
Vanderpump, M. P. J. (2011) · British Medical Bulletin · doi:10.1093/bmb/ldr030 · Cited by 1,179
(1975) · Annals of Internal Medicine · doi:10.7326/0003-4819-82-2-292_1 · Cited by 641
Saravanan, P., Chau, W. ‐., Roberts, N., Vedhara, K., Greenwood, R., & Dayan, C. M. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.01654.x · Cited by 514
Conversion of Thyroxine (T4) to triiodothyronine (T3) in athyreotic human subjects
Braverman, L. E., Ingbar, S. H., & Sterling, K. (1970) · Journal of Clinical Investigation · doi:10.1172/jci106304 · Cited by 485 · cited 1×
“This strategy has been justified with the knowledge that, in humans, the iodothyronine deiodinases in peripheral tissues produce most of the circulating active form of thyroid hormone, triiodothyronine (T3), via conversion from thyroxine (T4) (4).”
BackgroundThe Thyroid: A Fundamental and Clinical Text
WERNER, S. C. (1956) · The American Journal of the Medical Sciences · doi:10.1097/00000441-195610000-00020 · Cited by 460
2012 ETA Guidelines: The Use of L-T4 + L-T3 in the Treatment of Hypothyroidism
Wiersinga, W. M., Duntas, L., Fadeyev, V., Nygaard, B., & Vanderpump, M. P. J. (2012) · European Thyroid Journal · doi:10.1159/000339444 · Cited by 437 · cited 2×
“The dogma in clinical thyroidology that LT4 monotherapy at doses that normalize serum TSH is sufficient to restore euthyroidism (1, 2) has come into question as evidence suggests a significant proportion of patients treated with LT4 continue to experience residual symptoms of hypothyroidism, including psychological (6…”
BackgroundFish, L. H., Schwartz, H. L., Cavanaugh, J., Steffes, M. W., Bantle, J. P., & Oppenheimer, J. H. (1987) · New England Journal of Medicine · doi:10.1056/nejm198703263161302 · Cited by 353 · cited 1×
“While this phenomenon has been noted in the setting of LT4 monotherapy for the last four decades, (3, 8, 22–29) there are at least two prior, smaller, studies showing that serum T3 levels can be normal in LT4-treated individuals with normal serum TSH (28, 30).”
BackgroundLevothyroxine Monotherapy Cannot Guarantee Euthyroidism in All Athyreotic Patients
Gullo, D., Latina, A., Frasca, F., Le Moli, R., Pellegriti, G., & Vigneri, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022552 · Cited by 307 · cited 1×
“One hypothesis to explain this phenomenon is that serum levels of T3 might not be fully normalized, (8) ie, T4-to-T3 conversion in these patients may be insufficient to restore levels to those achieved when thyroidal secretion of T3 is intact.”
Background
Research works printed but not linked: 1
- Medicines Use and Spending in the U.S.: A Review of 2015 and Out- look to 2020. Parsippany, NJ: IMS Institute for Healthcare Infor- matics; 2016.
Cited by
Deiodinases and their intricate role in thyroid hormone homeostasis
Luongo, C., Dentice, M., & Salvatore, D. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0218-2 · Cited by 332
Paradigms of dynamic control of thyroid hormone signaling
Bianco, A. C., Dumitrescu, A., Gereben, B., Ribeiro, M. O., Fonseca, T. L., Fernandes, G. W., & Bocco, B. M. L. C. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00275 · Cited by 293
Self-citationAn Online Survey of Hypothyroid Patients Demonstrates Prominent Dissatisfaction
Peterson, S. J., Cappola, A. R., Castro, M. R., Dayan, C. M., Farwell, A. P., Hennessey, J. V., Kopp, P. A., Ross, D. S., Samuels, M. H., Sawka, A. M., et al. (2018) · Thyroid · doi:10.1089/thy.2017.0681 · Cited by 231
“Among National Health and Nutrition Examination Survey (NHANES) participants, LT4-treated patients with a normal serum TSH exhibit a 15–20% decrease in the ratio of circulating T3/T4 (18), and about 15% of these patients may not maintain normal serum T3 levels (19).”
InfluentialSelf-citationJonklaas, J., Bianco, A. C., Cappola, A. R., Celi, F. S., Fliers, E., Heuer, H., McAninch, E. A., Moeller, L. C., Nygaard, B., Sawka, A. M., et al. (2021) · Thyroid® · doi:10.1089/thy.2020.0720 · Cited by 172
Self-citationTaylor, P. N., Medici, M. M., Hubalewska-Dydejczyk, A., & Boelaert, K. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01614-3 · Cited by 128
Type 2 deiodinase polymorphism causes ER stress and hypothyroidism in the brain
Jo, S., Fonseca, T. L., Bocco, B. M. L. C., Fernandes, G. W., McAninch, E. A., Bolin, A. P., Da Conceição, R. R., Werneck-de-Castro, J. P., Ignacio, D. L., Egri, P., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci123176 · Cited by 107
Self-citationThyroid Hormone Action and Energy Expenditure
Yavuz, S., Salgado Nunez del Prado, S., & Celi, F. S. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2018-00423 · Cited by 95
“Despite this uncertainty, the belief that minimal changes in TH signaling cause considerable perturbation in EE, symptoms and clinical indices of euthyroidism are widespread, even in the absence of abnormalities in the TSH or TH levels [7, 8].”
BackgroundMcAninch, E. A., Rajan, K. B., Miller, C. H., & Bianco, A. C. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01361 · Cited by 94
Self-citationShakir, M. K. M., Brooks, D. I., McAninch, E. A., Fonseca, T. L., Mai, V. Q., Bianco, A. C., & Hoang, T. D. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab478 · Cited by 92
“There is now a consensus that a fraction of the LT4-treated hypothyroid patients with normal serum TSH levels remains symptomatic (6,7,23,24).”
BackgroundSelf-citationOptimal thyroid hormone replacement
Jonklaas, J. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab031 · Cited by 89
Mitchell, A. L., Hegedüs, L., Žarković, M., Hickey, J. L., & Perros, P. (2021) · Clinical Endocrinology · doi:10.1111/cen.14340 · Cited by 81
Jonklaas, J., Bianco, A. C., Cappola, A. R., Celi, F. S., Fliers, E., Heuer, H., McAninch, E. A., Moeller, L. C., Nygaard, B., Sawka, A. M., et al. (2021) · European Thyroid Journal · doi:10.1159/000512970 · Cited by 78
Self-citationIndividualized Therapy for Hypothyroidism: Is T4 Enough for Everyone?
Ettleson, M. D., & Bianco, A. C. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa430 · Cited by 75
Self-citationTaylor, P. N., Lansdown, A., Witczak, J., Khan, R., Rees, A., Dayan, C. M., & Okosieme, O. (2023) · Thyroid Research · doi:10.1186/s13044-023-00149-5 · Cited by 72
“There is evidence that TSH normalisation does not necessarily optimise tissue thyroid status in individuals on levothyroxine [119].”
BackgroundHoermann, R., Midgley, J. E. M., Larisch, R., & Dietrich, J. W. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00364 · Cited by 69
“While the consequences of the altered ratios are widely unknown and require further study (88), implications for the interpretation of TSH measurements can be readily derived.”
BackgroundT3 levels and thyroid hormone signaling
Salas-Lucia, F., & Bianco, A. C. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1044691 · Cited by 66
Self-citationPerros, P., Van Der Feltz‐Cornelis, C., Papini, E., Nagy, E. V., Weetman, A. P., & Hegedüs, L. (2023) · Clinical Endocrinology · doi:10.1111/cen.14473 · Cited by 65
Hypothyroidism: The difficulty in attributing symptoms to their underlying cause
Jansen, H. I., Boelen, A., Heijboer, A. C., Bruinstroop, E., & Fliers, E. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1130661 · Cited by 63
“Clinical studies in euthyroid patients using L-T4 showed that FT4 concentrations in this group are significantly higher, and more often above the upper reference interval, than in non L-T4 treated people (32, 48, 49) indicating that in this group a higher upper reference limit may apply.”
ResultDayan, C., & Panicker, V. (2018) · Thyroid Research · doi:10.1186/s13044-018-0045-x · Cited by 62
Millan-Alanis, J. M., González-González, J. G., Flores-Rodríguez, A., Singh Ospina, N., Maraka, S., Moreno-Peña, P. J., Brito, J. P., González-Velázquez, C., & Rodríguez-Gutiérrez, R. (2021) · Thyroid® · doi:10.1089/thy.2021.0270 · Cited by 60
“Fatigue, decrease in health-related quality of life (QoL), and cognitive and psychological impairment are among the main complaints (2,8–11).”
Pathophysiological relevance of deiodinase polymorphism
Bianco, A. C., & Kim, B. S. (2018) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000428 · Cited by 59
Self-citationLiothyronine and Desiccated Thyroid Extract in the Treatment of Hypothyroidism
Idrees, T., Palmer, S., Maciel, R. M. B., & Bianco, A. C. (2020) · Thyroid® · doi:10.1089/thy.2020.0153 · Cited by 58
“When compared with normal individuals with similar TSH levels, LT4-treated patients weigh *10 pounds more (14), exhibit a slightly lower basal metabolic rate (BMR) (15,17,18), and have higher serum cholesterol and low density lipoprotein levels (19–21), even as they are more likely to be on statin medications (14).”
BackgroundSelf-citationThyroxine and treatment of hypothyroidism: seven decades of experience
Mateo, R. C. I., & Hennessey, J. V. (2019) · Endocrine · doi:10.1007/s12020-019-02006-8 · Cited by 57
Ruiz-Núñez, B., Tarasse, R., Vogelaar, E. F., Dijck-Brouwer, J., & Muskiet, F. A. J. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00097 · Cited by 63
“This subgroup of T4-treated subjects exhibited 10–15% higher TT4 and FT4, but 5–10% lower TT3 and FT3 and a 15–20% lower T3/T4 ratio, as compared to 469 carefully matched healthy controls (88).”
BackgroundResultTHERAPY OF ENDOCRINE DISEASE: T4 + T3 combination therapy: is there a true effect?
Wiersinga, W. M. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0645 · Cited by 52
Hennessey, J. V., & Espaillat, R. (2018) · International Journal of Clinical Practice · doi:10.1111/ijcp.13062 · Cited by 49
Brain Fog in Hypothyroidism: What Is It, How Is It Measured, and What Can Be Done About It
Samuels, M. H., & Bernstein, L. J. (2022) · Thyroid · doi:10.1089/thy.2022.0139 · Cited by 64
“LT4 monotherapy does not normalize an array of systemic biomarkers and metabolic parameters in hypothyroid people (53,54).”
The relevance of T3 in the management of hypothyroidism
Salvatore, D., Porcelli, T., Ettleson, M. D., & Bianco, A. C. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00004-3 · Cited by 41
Self-citationRoss, D. S. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13410 · Cited by 42
Individualised requirements for optimum treatment of hypothyroidism: complex needs, limited options
Hoermann, R., Midgley, J. E. M., Larisch, R., & Dietrich, J. W. (2019) · Drugs in Context · doi:10.7573/dic.212597 · Cited by 41
Persistent hypothyroid symptoms in a patient with a normal thyroid stimulating hormone level
Jonklaas, J. (2017) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000355 · Cited by 38
Das, D., Banerjee, A., Jena, A. B., Duttaroy, A. K., & Pathak, S. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112613 · Cited by 50
Samuels, M. H., Kolobova, I., Antosik, M., Niederhausen, M., Purnell, J. Q., & Schuff, K. G. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00224 · Cited by 37
Emerging Therapies in Hypothyroidism
Bianco, A. C. (2024) · Annual Review of Medicine · doi:10.1146/annurev-med-060622-101007 · Cited by 44
Self-citationLiothyronine Use in Hypothyroidism and its Effects on Cancer and Mortality
Planck, T., Hedberg, F., Calissendorff, J., & Nilsson, A. (2021) · Thyroid® · doi:10.1089/thy.2020.0388 · Cited by 35
“LT4 treatment results in relatively higher normal levels of free thyroxine (T4) and relatively lower levels of free triiodothyronine (T3) than in euthyroid subjects without treatment (7,8), but the clinical relevance of this finding is unclear.”
Samuels, M. H., Kolobova, I., Niederhausen, M., Purnell, J. Q., & Schuff, K. G. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01203 · Cited by 35
T4 + T3 combination therapy: any progress?
Wiersinga, W. M. (2019) · Endocrine · doi:10.1007/s12020-019-02052-2 · Cited by 35
Azizi, F. (2020) · Thyroid · doi:10.1089/thy.2019.0814 · Cited by 35
“Patients using LT4 showed lower serum T3:T4 ratio, higher BMI, and differed in 12 of 52 objective and subjective variables, compared with healthy matched controls (21).”
Sustained release T3 therapy: animal models and translational applications
Idrees, T., Price, J. D., Piccariello, T., & Bianco, A. C. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00544 · Cited by 30
“For example, in association studies LT4treated patients that have a normal serum TSH weigh about 10 pounds more despite ingesting less calories; they report less physical activity and are more likely to be on statins and antidepressive therapy (23).”
BackgroundResultSelf-citationLankhaar, J. A. C., Kemler, E., Hofstetter, H., Collard, D. C. M., ZELISSEN, P. M. J., Stubbe, J. H., & BACKX, F. J. G. (2021) · Journal of Sports Sciences · doi:10.1080/02640414.2021.1940696 · Cited by 37
Critical Approach to Hypothyroid Patients With Persistent Symptoms
Biondi, B., Celi, F. S., & McAninch, E. A. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad224 · Cited by 34
Self-citationSerum thyrotropin and triiodothyronine levels in levothyroxine-treated patients
Ettleson, M. D., Prieto, W. H., Russo, P. S. T., de Sa, J., Wan, W., Laiteerapong, N., Maciel, R. M. B., & Bianco, A. C. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac725 · Cited by 25
Self-citationThe ups and downs of the thyroxine pro-hormone hypothesis
Galton, V. A. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.01.029 · Cited by 28
“Such studies are underway and the knowledge gained will be highly relevant to the on-going debates regarding the optimal prescription for TH replacement therapy in hypothyroidism (95,96).”
BackgroundLee, Y. K., Lee, H., Han, S., Jung, H., Shin, D. Y., Nam, K.-H., Chung, W. Y., & Lee, E. J. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8081106 · Cited by 24
Neves, J. S., Fontes‐Carvalho, R., Borges‐Canha, M., Leite, A. R., Martins, S., Oliveira, A. B. F. D., Guimarães, J. T., Carvalho, D. M., Leite-Moreira, A. F., & Azevedo, A. (2020) · European Thyroid Journal · doi:10.1159/000508407 · Cited by 31
“Furthermore, treatment with levothyroxine is usually associated with higher T4 and lower T3 levels compared with the general population [46], which may not completely restore the euthyroid state [61].”
BackgroundBorson‐Chazot, F., Terra, J., Goichot, B., & Caron, P. J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10071386 · Cited by 37
Long-term thionamide antithyroid treatment of Graves' disease
Azizi, F., Abdi, H., Amouzegar, A., & Moeini, A. S. H. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101631 · Cited by 31
The Swinging Pendulum in Treatment for Hypothyroidism: From (and Toward?) Combination Therapy
McAninch, E. A., & Bianco, A. C. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00446 · Cited by 24
“Indeed, it has been shown in a large population study that LT4treated patients exhibit higher BMIs and take more statins and anti-depressants than TSH-matched, healthy controls (15); this association could have been impacted by confounding and thus further investigation is indicated to confirm these results (15).”
BackgroundSelf-citationDa Conceição, R. R., Fernandes, G. W., Fonseca, T. L., Bocco, B. M. L. C., & Bianco, A. C. (2018) · Thyroid · doi:10.1089/thy.2018.0205 · Cited by 23
“Additionally, LT4-treated subjects reported an increased frequency of episodes of memory problems/ confusion and were less likely to report being in excellent/ good health (13).”
Self-citationEvaluating health outcomes in the treatment of hypothyroidism
Ettleson, M. D., & Papaleontiou, M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1026262 · Cited by 34
“In addition, there is a large body of evidence from levothyroxine-treated patients that subnormal energy expenditure (16–18), abnormal lipid metabolism (3, 19, 20), unresolved cognitive impairments (21), and decreased quality of life (QoL) (22, 23) were observed concurrently with normal TSH levels.”
BackgroundFunctional and Symptomatic Individuality in the Response to Levothyroxine Treatment
Hoermann, R., Midgley, J. E. M., Larisch, R., & Dietrich, J. W. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00664 · Cited by 22
“This dissolves the existing relationships in an individual prior to thyroidectomy, re-adjusting the setpoint and re-setting the equilibria between TSH, FT4, and FT3 in thyroid disease, compared to the healthy state (14, 15, 42, 78).”
BackgroundT4+T3 Combination Therapy: An Unsolved Problem of Increasing Magnitude and Complexity
Wiersinga, W. M. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.501 · Cited by 21
“A normal serum TSH level consequently does not necessarily indicate a euthyroid state at the tissue level [49].”
BackgroundBrigante, G., Santi, D., Boselli, G., Margiotta, G., Corleto, R., Monzani, M. L., Craparo, A., Locaso, M., Sperduti, S., Roy, N., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad172 · Cited by 23
Approach to the Patient Considering Long-term Antithyroid Drug Therapy for Graves’ Disease
Azizi, F., Mehran, L., Abdi, H., & Amouzegar, A. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae456 · Cited by 26
Combination Thyroid Hormone Replacement; Knowns and Unknowns
Taylor, P. N., Eligar, V., Muller, I., Scholz, A., Dayan, C., & Okosieme, O. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00706 · Cited by 21
“Prolonged exposure to this different ratio appeared to have adverse health outcomes as, LT4 treated individuals had higher a body mass index despite lower calorie consumption, reported less physical activity and were more likely to be taking antidepressants (14), although confounding remains a possibility.”
BackgroundResultMuraca, E., Ciardullo, S., Oltolini, A., Zerbini, F., Bianconi, E., Perra, S., Villa, M., Cannistraci, R., Castoldi, G., Pizzi, P., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa097 · Cited by 24
Sohn, S. Y., Seo, G. H., & Chung, J. H. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.680647 · Cited by 24
Dumitrescu, A. M., Hanlon, E. C., Arosemena, M., Duchon, O., Ettleson, M., Giurcanu, M., & Bianco, A. C. (2022) · Thyroid · doi:10.1089/thy.2021.0304 · Cited by 20
Self-citationRomero-Gómez, B., Guerrero-Alonso, P., Carmona‐Torres, J. M., Pozuelo‐Carrascosa, D. P., Laredo‐Aguilera, J. A., & Cobo‐Cuenca, A. I. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9123864 · Cited by 25
“Treated patients with normalized TSH levels have been found to have higher levels of T4 and fT4 than controls, higher T4/T3 or FT4/FT3 ratios [53–55], and lower serum T3 and FT3 concentrations [47].”
BackgroundResultCasula, S., Ettleson, M. D., & Bianco, A. C. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.04.003 · Cited by 21
Self-citationA Transgenic Mouse Model for Detection of Tissue-Specific Thyroid Hormone Action
Mohácsik, P., Erdélyi, F., Baranyi, M., Botz, B., Szabó, G., Tóth, M., Haltrich, I., Helyes, Z., Sperlágh, B., Tóth, Z., et al. (2017) · Endocrinology · doi:10.1210/en.2017-00582 · Cited by 22
Self-citationAzizi, F., Abdi, H., Cheraghi, L., & Amouzegar, A. (2020) · Thyroid · doi:10.1089/thy.2020.0433 · Cited by 20
“Inaddition, impairmentinpsychologicalwell-being(40),decreasedresting energyexpenditure(41),lowerserumT3:thyroxine(T4)ratio, andincreasedtotalandlow-densitylipoprotein-cholesterol(42) havebeenreportedinlevothyroxine-treatedpatientswhen comparedwithnormalcontrols.”
Idrees, T., Prieto, W. H., Casula, S., Ajith, A., Ettleson, M., Narchi, F. A. A., Russo, P. S. T., Fernandes, F., Johnson, J., Mayampurath, A., et al. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab038 · Cited by 17
“Furthermore, the analysis of the NHANES database identified 469 LT4-treated individuals who are ~50% more likely to be on statin medications than controls matched for age, sex, ethnic background, and serum TSH levels [15].”
BackgroundMethodSelf-citationThyroid Hormone Homeostasis in Levothyroxine-treated Patients: Findings From ELSA-Brasil
Penna, G. C., Bensenor, I. M., Bianco, A. C., & Ettleson, M. D. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae139 · Cited by 16
Self-citationSystemic Thyroid Hormone Status in Treated Graves’ Disease
Azizi, F., Amouzegar, A., Tohidi, M., Hedayati, M., Cheraghi, L., & Mehrabi, Y. (2019) · Intern J Endocrinol Metab · doi:10.5812/ijem.95385 · Cited by 19
“Previous studies have also shown the same results in the LT4 monotherapy settings, as compared to normal controls (2-4).”
MethodResultInfluentialManaging symptoms in hypothyroid patients on adequate levothyroxine: a narrative review
Razvi, S., Mrabeti, S., & Luster, M. (2020) · Endocrine Connections · doi:10.1530/ec-20-0205 · Cited by 15
Ito, M., Kawasaki, M., Danno, H., Kohsaka, K., Nakamura, T., Hisakado, M., Yoshioka, W., Kasahara, T., Kudo, T., Nishihara, E., et al. (2019) · Thyroid · doi:10.1089/thy.2019.0135 · Cited by 18
“Recently, in a large LT4-treated population with normal serum TSH, participants exhibited lower serum T3 levels and differed in terms of both objective and subjective measures (22).”
BackgroundBiondi, B., Pucci, M., Pontieri, G., Formisano, P., & Esposito, R. (2023) · Thyroid · doi:10.1089/thy.2023.0135 · Cited by 15
Molewijk, E., Fliers, E., Dreijerink, K. M. A., van Dooren, A. A., & Heerdink, E. R. (2024) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2024.100330 · Cited by 31
“Health risks that have been reported to be associated with suboptimal treatment for hypothyroidism may include cardiovascular disease, obesity, depression, pulmonary consequences, (female) fertility problems, and possibly dementia [12 – 16].”
Razvi, S., & Gottwald‐Hostalek, U. (2019) · Current Medical Research and Opinion · doi:10.1080/03007995.2019.1570769 · Cited by 18
Refractory hypothyroidism: unraveling the complexities of diagnosis and management
Quiroz-Aldave, J. E., Concepción-Zavaleta, M. J., Durand-Vásquez, M. D. C., Concepción-Urteaga, L. A., Gamarra-Osorio, E. R., Suárez-Rojas, J., Rafael-Robles, L. D. P., Paz-Ibarra, J., & Román-González, A. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.09.003 · Cited by 14
Increased fT4 concentrations in patients using levothyroxine without complete suppression of TSH
Jansen, H. I., Bult, M., Bisschop, P. H. L. T., Boelen, A., Heijboer, A. C., & Hillebrand, J. J. (2023) · Endocrine Connections · doi:10.1530/ec-22-0538 · Cited by 14
Lankhaar, J. A. C., Kemler, E., Stubbe, J. H., & BACKX, F. J. G. (2021) · Journal of Physical Activity and Health · doi:10.1123/jpah.2021-0230 · Cited by 20
“Explanations include the patient ’ s awareness of a chronic illness requiring lifelong dependency on medication, 6,17 inadequacy of levothyroxine monotherapy to restore physiological thyroid hormone concentrations of thyroxine and triiodothyronine at tissue level, as well as the presence of…”
BackgroundLevothyroxine treatment and cholesterol in hypothyroidism
Bianco, A. C., & Taylor, P. N. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0323-2 · Cited by 17
Self-citationBiondi, B. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02302 · Cited by 17
Shepelkevich, A. P., Dydyshka, Y. V., Yurenya, E., Лобашова, В. Л., Attanasio, R., Hegedűs, L. D., Nagy, E. V., Negro, R., Papini, E., & Perros, P. (2021) · Problems of Endocrinology · doi:10.14341/probl12828 · Cited by 14
Real Practice Assessment of Persistent Symptoms After Initiation of Levothyroxine
Hidalgo, J., Vallejo, B. A., Soto Jacome, C., Ayala, I. N., Cordova, S., Duran, M., Golembiewski, E., Toro-Tobon, D., & Brito, J. P. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2023.10.132 · Cited by 12
Hypothyroidism, comorbidity and health-related quality of life: a population-based study
Wouters, H. J. C. M., Wolffenbuttel, B. H. R., Kobold, A. C. M., Links, T. P., Huls, G. A., & van der Klauw, M. M. (2023) · Endocrine Connections · doi:10.1530/ec-23-0266 · Cited by 17
“A few studies addressed the question of whether the actual serum concentrations of FT4 and FT3 during replacement therapy influence HRQoL, with conflicting results (3, 7, 8, 9).”
ResultRaij, T., & Raij, K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1358404 · Cited by 16
Jonklaas, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.934003 · Cited by 13
“Frontiers in Endocrinology 03 attention (21, 22).”
Luongo, C., De Stefano, M. A., Ambrosio, R., Volpe, F., Porcelli, T., Golia, V., Bellevicine, C., Troncone, G., Masone, S., Damiano, V., et al. (2023) · Thyroid · doi:10.1089/thy.2022.0472 · Cited by 11
LT4 and Slow Release T3 Combination: Optimum Therapy for Hypothyroidism?
Azizi, F., Amouzegar, A., Mehran, L., & Abdi, H. (2020) · Intern J Endocrinol Metab · doi:10.5812/ijem.100870 · Cited by 14
“LT4 had significant impairment in psychological wellbeing (14) and lower resting energy expenditure compared to healthy controls (16) while demonstrating lower and even suppressed serum TSH concentrations (15).”
BackgroundInfluentialQuality of Life After Thyroidectomy for Hashimoto Disease in Patients With Persistent Symptoms
Thatipamala, P., Noel, J. E., & Orloff, L. A. (2020) · Ear Nose & Throat Journal · doi:10.1177/0145561320967332 · Cited by 10
“While multiple studies have addressed relief of local pain/pressure, dysphagia, or voice complaints after thyroidectomy for Hashimoto goiter,(23-25) it is frequently the noncompressive symptoms that present the greatest challenge in disease management and persist despite biochemical euthyroidism.(26) This study specif…”
BackgroundZhang, H., Tong, W., Zeng, W., Luo, H., Zhang, L., Feng, J., Xiao, Y., & Wang, G. A. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1627787 · Cited by 19
“To date, most patients on LT4 with normal serum TSH exhibit a decreased serum Frontiers in Endocrinology 04 frontiersin.org T3/T4 ratio (39).”
Azizi, F., Saadat, N., Takyar, M. A., Abdi, H., Mehran, L., & Amouzegar, A. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.1476 · Cited by 14
Riis, K. R., Larsen, C. B., & Bonnema, S. J. (2024) · Thyroid® · doi:10.1089/thy.2023.0649 · Cited by 10
Razvi, S., Ryan, V., Ingoe, L. E., Pearce, S. H. S., & Wilkes, S. (2019) · European Thyroid Journal · doi:10.1159/000504047 · Cited by 16
Galton, V. A., Martinez, M. E., Dragon, J. A., Germain, D. L. S., & Hernández, A. (2020) · Thyroid · doi:10.1089/thy.2020.0508 · Cited by 11
“Much has been written regarding the pros and cons of administering various TH regimens in the treatment of hypothyroidism (44,45).”
BackgroundHoermann, R., Midgley, J. E. M., Larisch, R., & Dietrich, J. W. (2020) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2020.100219 · Cited by 12
“comes, most strongly dyslipidaemia [59].”
Payer, J., Jackuliak, P., Kužma, M., Džupon, M., & Vaňuga, P. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1067029 · Cited by 15
“Condition of SCH might evolve to chronic pathology named overt hypothyroidism and, so far, the widest prescribed treatment to counteract those cases is Levothyroxine (LT4), a synthetic hormone administered to increase serum T4/T3 ratios and to normalize serum level of TSH (10, 11).”
BackgroundLarsen, C. B., Winther, K. H., Cramon, P. K., Rasmussen, Å. K., Feldt‐Rasmussen, U., Grøenvold, M., Bjørner, J. B., Hegedűs, L. D., Watt, T., & Bonnema, S. J. (2023) · Thyroid Research · doi:10.1186/s13044-023-00178-0 · Cited by 12
“When euthyroid, defined as normalized plasma thyro-tropin (TSH), many patients on LT4 substitution show relatively low levels of plasma triiodothyronine (T3) [16–18].”
BackgroundHidalgo, J., Lincango-Naranjo, E. P., Cordova-Madera, S., Ruiz-Arellanos, K., Wenczenovicz, C., Ponce, O. J., Álvarez‐Villalobos, N. A., Rao, A., Ospina, N. S., Maraka, S., et al. (2024) · Endocrine · doi:10.1007/s12020-024-03816-1 · Cited by 11
“In addition, clinicians caring for patients with persistent symptoms face the challenge of not having evidence-based recommendations to guide their next steps [6].”
Hypothyroid Symptoms in Levothyroxine-Treated Patients
Freeman, M., Adunlin, G. A., Mercadel, C., Danzi, S., & Klein, I. (2019) · INNOVATIONS in pharmacy · doi:10.24926/iip.v10i3.2026 · Cited by 8
Takahashi, S., Ito, M., Masaki, Y., Okazaki‐Hada, M., Minakata, M., Kohsaka, K., Nakamura, T., Kasahara, T., Kudo, T., Nishihara, E., et al. (2020) · Endocrine Journal · doi:10.1507/endocrj.ej20-0542 · Cited by 10
Markantes, G. Κ., Dimitropoulos, K., Mamali, I., Tseti, I. K., Sakellaropoulos, G. C., Markou, K. B., & Michalaki, M. A. (2020) · European Thyroid Journal · doi:10.1159/000508216 · Cited by 8
Beltrão, F. E. D. L., Carvalhal, G., Meneghini, V., Matos, D. A. R., Beltrão, D. C. D. A., Andrade, B. A. R. M., Beltrão, F. N. D. L., Ramos, H. E., Ribeiro, M. O., Golovko, G., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf367 · Cited by 7
Self-citationSaadat, N., Azizi, F., Abdi, H., & Amouzegar, A. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01823-5 · Cited by 7
Dutt, R., Malik, K. C., Karwa, M., & Jain, G. K. (2020) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v10i3-s.4189 · Cited by 9
Treatment of subclinical hypothyroidism: assessing when treatment is likely to be beneficial
Leng, O., & Razvi, S. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1738924 · Cited by 8
“the active thyroid hormone T3 nor systemic biological markers of thyroid hormone signaling [40,41].”
BackgroundGökkaya, N., & Aydın, K. (2024) · Scientific Reports · doi:10.1038/s41598-024-78185-w · Cited by 8
“In NHANES participants, patients treated with LT4 experienced a 15–20% reduction in circulating T3/T4 ratios and normalizing serum TSH, with 15% of patients unable to achieve normal serum T3 levels 27 .”
Metadata
- Authors
- Peterson, S. J., McAninch, E. A., & Bianco, A. C.
- Affiliations
- Rush University Medical Center (US)
- Corresponding author
- Bianco, Antonio C.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2016-10-04
- Volume
- 101
- Issue
- 12
- Pages
- 4964-4973
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC6287526
- OpenAlex
- W2527838986
- Cited by
- 182
- References
- 29
- Citations by year
- 2026: 9 · 2025: 19 · 2024: 21 · 2023: 17 · 2022: 17 · 2021: 24 · 2020: 29 · 2019: 22 · 2018: 11 · 2017: 12
- FWCI
- 15.08
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Keywords
- levothyroxine monotherapy, hypothyroidism, thyroid-stimulating hormone, euthyroidism, free thyroxine, thyroid hormone levels, body mass index, metabolic equivalents, lipid profile, C-reactive protein, energy intake
- MeSH terms
- Adult, Aged, Cross-Sectional Studies, Female, Health Surveys, Humans, Hypothyroidism, Male, Middle Aged, Thyroid Function Tests, Thyrotropin, Thyroxine, Triiodothyronine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.